E Braunwald

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Heart failure
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts Electronic address
    JACC Heart Fail 1:1-20. 2013
  2. pmc Epidemiology of heart failure
    Veronique L Roger
    Department of Health Sciences Research and Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circ Res 113:646-59. 2013
  3. pmc Cardiovascular science: opportunities for translating research into improved care
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Invest 123:6-10. 2013
  4. doi request reprint The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Thorac Cardiovasc Surg 144:762-70. 2012
  5. pmc The rise of cardiovascular medicine
    Eugene Braunwald
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 33:838-45, 845a. 2012
  6. doi request reprint Unstable angina and non-ST elevation myocardial infarction
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 185:924-32. 2012
  7. ncbi request reprint Cardiology: how did we get here, where are we today and where are we going?
    Eugene Braunwald
    TIMI Study Group, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Can J Cardiol 21:1015-7. 2005
  8. doi request reprint Assessing the current role of platelet function testing
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I10-6. 2008
  9. doi request reprint The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I17-20. 2008
  10. doi request reprint Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I2-9. 2008

Collaborators

Detail Information

Publications150 found, 100 shown here

  1. doi request reprint Heart failure
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts Electronic address
    JACC Heart Fail 1:1-20. 2013
    ..While many of these therapies will improve the care of patients with HF, significant reductions in prevalence will require vigorous, multifaceted, preventive approaches...
  2. pmc Epidemiology of heart failure
    Veronique L Roger
    Department of Health Sciences Research and Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circ Res 113:646-59. 2013
    ..New models of patient-centered care that draw on community-based resources to support HF patients with complex coexisting conditions are needed to decrease hospitalizations...
  3. pmc Cardiovascular science: opportunities for translating research into improved care
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Invest 123:6-10. 2013
    ..Cumulatively, it seems likely that the clinical advances emerging from ongoing research will, in the foreseeable future, reduce the number of deaths in the industrialized world from cardiovascular disease...
  4. doi request reprint The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Thorac Cardiovasc Surg 144:762-70. 2012
    ..TIMI is currently conducting 7 large trials worldwide on novel agents designed to reduce the morbidity and mortality of a variety of cardiovascular disorders...
  5. pmc The rise of cardiovascular medicine
    Eugene Braunwald
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 33:838-45, 845a. 2012
    ..Research and practice are increasingly conducted in cardiovascular centres and institutes. It is likely that in the future, a greater emphasis will be placed on prevention, which will be enhanced by genetic information...
  6. doi request reprint Unstable angina and non-ST elevation myocardial infarction
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 185:924-32. 2012
    ..Those at low risk should continue to receive intensive antiischemic and antithrombotic therapy. At discharge, patients should receive intensive lipid-lowering therapy with high doses of a statin, as tolerated...
  7. ncbi request reprint Cardiology: how did we get here, where are we today and where are we going?
    Eugene Braunwald
    TIMI Study Group, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Can J Cardiol 21:1015-7. 2005
  8. doi request reprint Assessing the current role of platelet function testing
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I10-6. 2008
    ..The ideal platelet function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable...
  9. doi request reprint The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I17-20. 2008
    ..Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation...
  10. doi request reprint Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I2-9. 2008
    ..Currently, it appears that the use of GP IIb/IIIa antagonists might be most beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation myocardial infarction and elevated troponin levels...
  11. doi request reprint Adventures in cardiovascular research
    Eugene Braunwald
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Circulation 120:170-80. 2009
    ..The article ends with some general comments on conducting research and the rewards that can come with this activity...
  12. doi request reprint Investigating the mechanisms of hyporesponse to antiplatelet approaches
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I21-7. 2008
    ..Results from these studies could cause a paradigm shift toward individualized antiplatelet therapy, improving predictability of platelet inhibition, and diminishing the likelihood for hyporesponsiveness...
  13. doi request reprint Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I28-35. 2008
    ..Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences...
  14. ncbi request reprint Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 108:III28-37. 2003
    ..Lower-risk patients should undergo early noninvasive stress testing. An intensive program of secondary prevention is mandatory and should be begun before hospital discharge...
  15. ncbi request reprint Changing the practice of cardiovascular medicine
    E Braunwald
    Department of Medicine, Harvard Medical School, Prudential Tower, Suite 1150, 800 Boylston Street, Boston, MA 02190, USA
    Atheroscler Suppl 2:27-30. 2001
    ....
  16. ncbi request reprint Epilogue: what do clinicians expect from imagers?
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:C101-3. 2006
  17. ncbi request reprint The Simon Dack lecture. Cardiology: the past, the present, and the future
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:2031-41. 2003
  18. doi request reprint Hypertrophic cardiomyopathy: the early years
    Eugene Braunwald
    Harvard Medical School, Boston, MA, USA
    J Cardiovasc Transl Res 2:341-8. 2009
    ..The recognition of this fourth and last major feature in 1959 makes 2009 the golden anniversary year marking completion of the description of the major features of HOCM...
  19. ncbi request reprint Reducing myocardial injury by minimizing imbalance between oxygen supply and demand
    Eugene Braunwald
    Harvard Medical School, and Brigham and Women s Hospital, Boston, MA, USA
    Anesthesiology 107:161-3. 2007
    ..We conclude that the hemodynamic status and neurohumoral background at the time of coronary occlusion and for at least 3 hr thereafter can alter the extent and severity of myocardial ischemic injury and myocardial necrosis...
  20. doi request reprint Clinical efforts to reduce myocardial infarct size--the next step
    Eugene Braunwald
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Cardiovasc Pharmacol Ther 16:349-53. 2011
    ..A plan for the testing of these interventions in patients with acute myocardial infarction is described...
  21. pmc The American Society for Clinical Investigation, 1952--1975: a personal perspective
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Invest 118:1228-30. 2008
    ..I focus attention on the sociological aspects of the Atlantic City meetings and the critically important role these meetings played in the evolution of academic medicine during the third quarter of the 20th century...
  22. doi request reprint Biomarkers in heart failure
    Eugene Braunwald
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and the Department of Medicine, Harvard Medical School, Boston, USA
    N Engl J Med 358:2148-59. 2008
  23. ncbi request reprint Contemporary evaluation and management of hypertrophic cardiomyopathy
    Eugene Braunwald
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 106:1312-6. 2002
  24. ncbi request reprint Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification
    Benjamin M Scirica
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:821-6. 2002
    ..Given their high risk for adverse events, patients with secondary UAP should be treated aggressively...
  25. ncbi request reprint Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1593-601. 1999
    ..Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non-Q-wave myocardial infarction (UA/NQMI)...
  26. ncbi request reprint Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy
    E M Antman
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:326-30. 1998
    ..We sought to determine whether the rapid bedside assay for troponin T identified patients at risk for a more complicated hospital stay and a higher rate of adverse clinical events...
  27. ncbi request reprint Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators
    E M Antman
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 21:1944-53. 2000
    ..reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses of reteplase without abciximab and were at least as high as for full dose reteplase alone..
  28. ncbi request reprint Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 344:1879-87. 2001
    ..There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation...
  29. ncbi request reprint Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 134:622-30. 1997
    ..The availability of a reliable, noninvasive serum marker of reperfusion may permit early identification of patients with occlusion after thrombolysis who might benefit from further interventions...
  30. ncbi request reprint Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
    C P Cannon
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:149-56. 2000
    ..Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events...
  31. ncbi request reprint Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 98:839-44. 1998
    ..We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk...
  32. ncbi request reprint Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass, USA
    Circulation 105:1642-9. 2002
    ..ENTIRE-TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab...
  33. ncbi request reprint TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:2031-7. 2000
    ..Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice...
  34. ncbi request reprint Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
    J A de Lemos
    Cardiovascular Division, Brigham and Women s Hospital, Boston Massachusetts, USA
    Circulation 101:239-43. 2000
    ..We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation...
  35. ncbi request reprint The year in non-ST-segment elevation acute coronary syndrome
    Robert P Giugliano
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1386-95. 2007
  36. ncbi request reprint Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 141:742-50. 2001
    ..The optimal heparin dose as an adjunct to fibrinolysis and its role in causing intracranial hemorrhage (ICH) is unclear...
  37. ncbi request reprint Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, The Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 80:21-6. 1997
    ....
  38. ncbi request reprint Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
    F M Sacks
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Circulation 97:1446-52. 1998
    ..Although LDL lowering has been shown to reduce recurrent coronary events in patients with coronary heart disease, little direct information is available on the extent of LDL lowering required to achieve this outcome...
  39. ncbi request reprint Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:739-47. 1999
    ....
  40. ncbi request reprint Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 22:1702-15. 2001
    ..These findings have important implications in the design and interpretation of international studies, identify under- and over-utilized therapies, and support further study of treatments with marked worldwide variations...
  41. ncbi request reprint Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
    E M Antman
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 100:1602-8. 1999
    ..A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points...
  42. ncbi request reprint Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
    J A de Lemos
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:373-8. 2000
    ..We evaluated the combination of a baseline myoglobin assay and early (60- to 90-minute) ST resolution for risk stratification after ST-segment elevation myocardial infarction...
  43. ncbi request reprint Benefit of an early invasive management strategy in women with acute coronary syndromes
    Ruchira Glaser
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    JAMA 288:3124-9. 2002
    ..However, these studies were performed prior to the widespread use of platelet glycoprotein IIb/IIIa inhibitors and intracoronary stents...
  44. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  45. ncbi request reprint The year in non-ST-segment elevation acute coronary syndromes
    Robert P Giugliano
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:386-95. 2006
  46. doi request reprint Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  47. ncbi request reprint Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  48. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  49. ncbi request reprint Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience)
    M J Schweiger
    Department of Medicine, Baystate Medical Center, Springfield, Massachusetts 01199, USA
    Am J Cardiol 88:831-6. 2001
    ..e., TIMI 3 flow at 90 minutes) who did not undergo revascularization (p = 0.02). Thus, early PCI following AMI is associated with excellent outcomes. Randomized trials of an early invasive strategy following thrombolysis are warranted...
  50. ncbi request reprint Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Circulation 103:2550-4. 2001
    ..These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI...
  51. ncbi request reprint The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
    E M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 284:835-42. 2000
    ..Patients with unstable angina/non-ST-segment elevation myocardial infarction (MI) (UA/NSTEMI) present with a wide spectrum of risk for death and cardiac ischemic events...
  52. ncbi request reprint The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia
    C P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 30:133-40. 1997
    ..We sought to determine the prognostic value of the admission electrocardiogram (ECG) in patients with unstable angina and non-Q wave myocardial infarction (MI)...
  53. ncbi request reprint Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 152:668-75. 2006
    ..Early restoration of epicardial flow before primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with improved clinical outcomes...
  54. ncbi request reprint Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
    ..We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect...
  55. doi request reprint Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Elliott M Antman
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2028-33. 2008
    ....
  56. doi request reprint Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  57. pmc Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  58. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  59. ncbi request reprint C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:1460-5. 1998
    ....
  60. ncbi request reprint Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction
    J S Hochman
    Department of Medicine, St Luke s Roosevelt Hospital Center and Columbia University, New York, New York 10025, USA
    J Am Coll Cardiol 30:141-8. 1997
    ..Women and men enrolled in the Thrombolysis in Myocardial Infarction (TIMI) IIIB trial of unstable angina and non-Q wave myocardial infarction (MI) were evaluated to determine gender differences in characteristics and outcome...
  61. doi request reprint Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Interv 3:806-11. 2010
    ..This study sought to determine angiographic and clinical outcomes among patients with acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on 12-lead electrocardiogram (ECG)...
  62. ncbi request reprint Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy
    V S Srinivas
    Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
    Am Heart J 142:29-36. 2001
    ..A low 12-hour myoglobin level (< or = 239 ng/mL in this substudy) identifies such patients at low risk and could potentially assist in early risk stratification and triage after ST-segment elevation myocardial infarction...
  63. ncbi request reprint Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events
    M A Pfeffer
    Department of Medicine, Brigham and Women s Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 33:125-30. 1999
    ..We sought to assess the influence of baseline lipid levels on coronary event rates and the effectiveness of pravastatin therapy in the Cholesterol And Recurrent Events (CARE) study...
  64. ncbi request reprint First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials
    R P Giugliano
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 140:81-93. 2000
    ..RPR 109891 is a modified tetrapeptide glycoprotein IIb/IIIa inhibitor available in intravenous and oral formulations. Two phase II dose-ranging studies were performed to investigate pharmacodynamics and safety in acute coronary syndromes...
  65. ncbi request reprint Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 35:358-62. 2000
    ....
  66. ncbi request reprint Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy
    D A Morrow
    Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1812-7. 2000
    ....
  67. ncbi request reprint A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy
    D A Morrow
    TIMI Trials Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 358:1571-5. 2001
    ..Available models for predicting mortality in STEMI include up to 45 variables, but have consistently shown advanced age, increased heart rate, and decreased blood pressure to be among the strongest predictors...
  68. ncbi request reprint Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
    C Michael Gibson
    TIMI Study Group and the Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 110:679-84. 2004
    ....
  69. ncbi request reprint Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction
    Juhana Karha
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 92:913-8. 2003
    ..In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates...
  70. doi request reprint Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009
    ....
  71. ncbi request reprint Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  72. ncbi request reprint Left ventricular remodeling and ventricular arrhythmias after myocardial infarction
    Martin St John Sutton
    Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 107:2577-82. 2003
    ....
  73. ncbi request reprint Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes
    James A de Lemos
    TIMI Study Group, Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas, Southwestern Medical School, Dallas, TX 75390 9047, USA
    Circulation 107:690-5. 2003
    ..MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction...
  74. ncbi request reprint Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group
    C M Gibson
    Department of Medicine, The University of California San Francisco, 94118, USA
    Am J Cardiol 87:450-3, A6. 2001
    ..Thus, the 60-minute angiographic end point appears to be a valid alternative to that at 90 minutes and may permit earlier decisions regarding post-thrombolytic intervention...
  75. ncbi request reprint Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement
    G F Mitchell
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 96:4254-60. 1997
    ..There is increasing evidence of a link between conduit vessel stiffness and cardiovascular events, although the association has never been tested in a large post-myocardial infarction patient population...
  76. ncbi request reprint An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:223-9. 2002
    ..We evaluated the TIMI Risk Score for Unstable Angina and Non-ST Elevation Myocardial Infarction for predicting clinical outcomes and the efficacy of tirofiban in non-ST elevation acute coronary syndromes...
  77. ncbi request reprint Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3
    D A Morrow
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:1356-9. 2001
    ..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population...
  78. ncbi request reprint Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction
    Elliott M Antman
    TIMI Study Group and the Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:229-34. 2002
    ....
  79. ncbi request reprint Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    Michelle O'Donoghue
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS) has not been established...
  80. doi request reprint Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:2358-62. 2009
    ....
  81. ncbi request reprint B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ....
  82. ncbi request reprint Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction
    J Llevadot
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 22:2104-15. 2001
    ..There is a need for additional randomized trials in the current era to address both the appropriate selection of patients and timing of invasive procedures in ST-elevation acute myocardial infarction...
  83. doi request reprint Early versus delayed, provisional eptifibatide in acute coronary syndromes
    Robert P Giugliano
    TIMI Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 360:2176-90. 2009
    ..Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown...
  84. ncbi request reprint The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes
    J A de Lemos
    Thrombolysis in Myocardial Infarction Study Group, Boston, USA
    N Engl J Med 345:1014-21. 2001
    ....
  85. ncbi request reprint Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    Catheter Cardiovasc Interv 53:6-11. 2001
    ....
  86. ncbi request reprint Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 28:806-13. 2007
    ..To investigate the relationship between diabetes and inflammation and the potentially synergistic relationship between hyperglycaemia and inflammation on clinical outcomes in non ST-elevation ACS...
  87. ncbi request reprint Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Elliott M Antman
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 354:1477-88. 2006
    ..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose...
  88. ncbi request reprint C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)
    Nazanin Moghbeli
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:635-8. 2005
    ..0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease...
  89. ncbi request reprint Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ..This study sought to evaluate what set of factors correlate with higher or lower C-reactive protein (CRP) levels in patients receiving standard and intensive statin therapy...
  90. ncbi request reprint Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study
    Eldrin F Lewis
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:1446-53. 2003
    ..We sought to determine the predictors of heart failure (HF) development in long-term survivors of myocardial infarction (MI)...
  91. ncbi request reprint Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1047-51. 2007
    ..On the basis of these findings, 1 death was prevented for every 95 patients treated with high-dose statin therapy for 2 years. The results of this pooled analysis provide further evidence for early intensive statin therapy after ACS...
  92. ncbi request reprint Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ....
  93. pmc Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    Eugene Braunwald
    Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 351:2058-68. 2004
    ..ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure...
  94. ncbi request reprint Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial
    D A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:2405-12. 2001
    ....
  95. ncbi request reprint Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 87:636-9, A10. 2001
    ..2% vs 3.2% to 3.6% for WBC count < 10,000; p < 0.000). With its simplicity and widespread availability, WBC count could serve as a simple, inexpensive, new tool for risk stratification in acute coronary syndromes...
  96. ncbi request reprint Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II
    E M Antman
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:928-33. 2002
    ..When evaluating new reperfusion regimens for ST elevation MI, it is important to adjust for factors that influence the likelihood of achieving normal epicardial flow and complete ST resolution...
  97. ncbi request reprint VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 102:1886-92. 2000
    ..Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps because of the metabolic heterogeneity among VLDL particles, the main carriers of triglycerides in plasma...
  98. ncbi request reprint Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  99. ncbi request reprint Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients...
  100. ncbi request reprint Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy
    Brad G Angeja
    Cardiovascular Division, Department of Medicine, University of California, San Francisco, Calif 94143, USA
    Am Heart J 144:649-56. 2002
    ..We studied the angiographic and electrocardiographic responses to thrombolytic agents in patients with diabetes; in particular ST-segment resolution as a measure of microvascular flow...
  101. ncbi request reprint Soluble CD40L: risk prediction after acute coronary syndromes
    Nerea Varo
    Donald W Reynolds Cardiovascular Clinical Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 108:1049-52. 2003
    ..This study tested the hypothesis that plasma sCD40L, alone or in combination with troponin (cTnI) or C-reactive protein (CRP), may identify patients with acute coronary syndromes at heightened risk for recurrent cardiac events...